Rigel Pharmaceuticals | RIGL - Sales Revenues

Stock Price
29.64
Daily Change
0.01 0.03%
Monthly
-13.21%
Yearly
50.46%
Q1 Forecast
33.68

Rigel Pharmaceuticals reported $55.31M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Agenus USD 24.07M 2.77M Mar/2025
Amgen USD 9.9B 340M Dec/2025
Anika Therapeutics USD 26.17M 12.58M Mar/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Celldex Therapeutics USD 121K 769K Dec/2025
Daiichi Sankyo JPY 558.11B 57.35B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Heron Therapeutics USD 32.81M 3.21M Sep/2024
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Veracyte USD 140.6M 8.7M Dec/2025